The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia
Open accessAbstract
OBJECTIVE—This study evaluated the effect of a atorvastatin-fenofibrate combination on lipid profile, in comparison to each drug alone, in patients with type 2 diabetes and combined hyperlipidemia (CHL). RESEARCH DESIGN AND METHODS—A total of 120 consecutive patients, who were free of coronary artery disease (CAD) at entry, were studied for a period of 24 weeks. These patients were randomly assigned to atorvastatin (20 mg/day, n = 40), micronized fenofibrate (200 mg/day, n = 40), or a combination of both (atorvastatin 20 mg/day plus fenofibrate 200 mg/day, n = 40). The effect of treatment on LDL cholesterol, triglycerides (TGs), HDL cholesterol, apolipoprotein A-I and B, lipoprotein(a), and plasma fibrinogen (PF) was recorded. Moreover, the percentage of patients that reached the American Diabetes Association treatment goals and the estimated CAD risk status were calculated. RESULTS—No patient was withdrawn from the study because of side effects. The atorvastatin-fenofibrate combination reduced total cholesterol by 37%, LDL cholesterol by 46%, TGs by 50%, and PF by 20%, whereas it increased HDL cholesterol by 22% (P < 0.0001 for all). These changes were significantly better than those of both monotherapies. Of the patients on drug combination, 97.5% reached the LDL cholesterol treatment goal of <100 mg/dl, 100% reached the desirable TG levels of <200 mg/dl, and 60% reached the optimal HDL cholesterol levels of >45 mg/dl. These rates were significantly higher than those of both monotherapies. Combined treatment reduced the 10-year probability for myocardial infarction from 21.6 to 4.2%. CONCLUSIONS—The atorvastatin-fenofibrate combination has a highly beneficial effect on all lipid parameters and PF in patients with type 2 diabetes and CHL. It improved patients’ CAD risk status significantly more than each drug alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623 · cited 2×
“In this study, patients with diabetes in the original report (n 202 with the old ADA criteria) were benefited more (55% reduction in coronary mortality) than nondiabetic patients (5).”
Assmann, G., Cullen, P., & Schulte, H. (2002) · Circulation · doi:10.1161/hc0302.102575 · Cited by 1,541
Jones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067
Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., Wexler, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 921
Bucala, R., Makita, Z., Vega, G., Grundy, S., Koschinsky, T., Cerami, A., & Vlassara, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9441 · Cited by 474
Haffner, S. M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2661 · Cited by 441
Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy
Pierce, L. R. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450010075034 · Cited by 428
Bakker-Arkema, R. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530260042029 · Cited by 407
Guerin, M., Lassel, T. S., Le Goff, W., Farnier, M., & Chapman, M. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.1.189 · Cited by 237
Dart, A., Jerums, G., Nicholson, G., d'Emden, M., Hamilton-Craig, I., Tallis, G., Best, J., West, M., Sullivan, D., Braes, P., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00280-4 · Cited by 187
The role of small, dense low density lipoprotein (LDL): a new look
Packard, C., Caslake, M., & Shepherd, J. (2000) · International Journal of Cardiology · doi:10.1016/s0167-5273(99)00107-2 · Cited by 171
Ellen, R. L. B., & McPherson, R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00040-x · Cited by 169
Athyros, V. G., Papageorgiou, A. A., Hatzikonstandinou, H. A., Didangelos, T., Carina, M., Kranitsas, D. F., & Kontopoulos, A. G. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00430-x · Cited by 157
Self-citationFibrates, dyslipoproteinaemia and cardiovascular disease
Watts, G. F., & Dimmitt, S. B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199912000-00011 · Cited by 151
Frost, R. J., Otto, C., Geiss, H. C., SCHWANDT, P., & Parhofer, K. G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01270-4 · Cited by 127
Burnett, J. R., Wilcox, L. J., Telford, D. E., Kleinstiver, S. J., Barrett, P. H. R., Newton, R. S., & Huff, M. W. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.2589 · Cited by 99
Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety
Gavish, D., Leibovitz, E., Shapira, I., & Rubinstein, A. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00646.x · Cited by 89
Gemfibrozil Alone and in Combination With Lovastatin for Treatment of Hypertriglyceridemia in NIDDM
Garg, A., & Grundy, S. M. (1989) · Diabetes · doi:10.2337/diab.38.3.364 · Cited by 85
Le, N., Innis‐Whitehouse, W., Li, X., Bakker-Arkema, R. G., Black, D. M., & Brown, W. V. (2000) · Metabolism · doi:10.1016/s0026-0495(00)91169-7 · Cited by 75
Plenz, G. A. M., Koenig, C., Severs, N. J., & Robenek, H. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.11.2489 · Cited by 75
Fibrinogen and cardiovascular risk
Heinrich, J., & Assmann, G. (1995) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199506000-00004 · Cited by 66
Kontopoulos, A., Athyros, V., Papageorgiou, A., Hatzikonstandinou, H. A., Mayroudi, M. C., & Boudoulas, H. (1996) · Coronary Artery Disease · doi:10.1097/00019501-199611000-00009 · Cited by 62
Self-citationGoudevenos, J. A., Bairaktari, E. T., Chatzidimou, K. G., Milionis, H. J., Mikhailidis, D. P., & Elisaf, M. (2000) · Current Medical Research and Opinion · doi:10.1185/030079901750120204 · Cited by 57
Kiortsis, D. N., Millionis, H., Bairaktari, E. T., & Elisaf, M. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000213 · Cited by 56
Feher, M. D., Foxton, J., Banks, D., Lant, A. F., & Wray, R. (1995) · Heart · doi:10.1136/hrt.74.1.14 · Cited by 53
Comparative study of HMG-CoA reductase inhibitors on fibrinogen
Rosenson, R. S., Tangney, C., & Schaefer, E. J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00590-6 · Cited by 46
Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control
Tan, C., Chew, L. S., Tai, E. S., Chio, L. F., Lim, H., Loh, L. M., & Shepherd, J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00497-4 · Cited by 26
Rustemeijer, C., Schouten, J. A., Voerman, H. J., Hensgens, H. E. S. J., Donker, A. J. M., & Heine, R. J. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(200003/04)16:2<82::aid-dmrr89>3.0.co;2-g · Cited by 22
Diabetes: Statins, fibrates, or both?
Farnier, M., & Picard, S. (2001) · Current Atherosclerosis Reports · doi:10.1007/s11883-001-0006-y · Cited by 20
Athyros, V. G., Papageorgiou, A. A., Hagikonstantinou, H. J., Papadopoulos, G. V., Zamboulis, C. X., & Kontopoulos, A. G. (1994) · Clinical Drug Investigation · doi:10.1007/bf03258465 · Cited by 13
Self-citation
Cited by
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss, R. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1496 · Cited by 756
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Metadata
- Authors
- Athyros, V. G., Papageorgiou, A. A., Athyrou, V. V., Demitriadis, D. S., & Kontopoulos, A. G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2002-07-01
- Volume
- 25
- Issue
- 7
- Pages
- 1198-1202
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2106340207
- Cited by
- 257
- References
- 36
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.